## HCA: HCA Healthcare, Inc. - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 1.29 indicates fundamental undervaluation. Quality metrics strong (ROE 136%, ROA 12%). Consistent execution (4/4 quarters beat estimates). Caution: momentum weakening (-2.3% MRS).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($441.72)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 4
- **Sentiment:** Bullish (Bullish: 2, Bearish: 1)

**1. Ten-Year Tally: HCA Healthcare Stock Delivers $43 Bil Gain**
- Source: Trefis | 20251217T061509 | Bullish | Relevance: 100%
- This article from Trefis discusses the ten-year performance of HCA Healthcare stock, highlighting a $43 billion gain. It appears to be an introductory piece to a detailed financial analysis or model on their platform.

**2. Why HCA Healthcare (HCA) is a Top Growth Stock for the Long-Term**
- Source: www.sharewise.com | 20251216T214257 | Bullish | Relevance: 100%
- HCA Healthcare (HCA) is identified as a top growth stock due to its strong financial health and promising future outlook, earning an "A" Growth Style Score and "A" VGM Score from Zacks. The company, a leading operator of acute care hospitals, is projected to see a 24.7% year-over-year earnings growth for the current fiscal year, with analysts revising estimates upwards. Investors looking for companies with high growth potential should consider HCA, particularly given its Zacks Rank #3 (Hold) combined with excellent Style Scores.

**3. HCA Healthcare Chief Nurse Executive Sammie Mosier dies at 49**
- Source: Modern Healthcare | 20251216T212557 | Bearish | Relevance: 100%
- Sammie Mosier, the chief nurse executive and senior vice president at HCA Healthcare, has died at the age of 49. Mosier dedicated nearly three decades of her career to HCA Healthcare.

**4. 4,600 Shares in ResMed Inc. $RMD Purchased by Sanders Morris Harris LLC**
- Source: MarketBeat | 20251217T122421 | Neutral | Relevance: 75%
- Sanders Morris Harris LLC has acquired a new position in ResMed Inc. (NYSE:RMD), purchasing 4,600 shares valued at approximately $1.26 million. Other institutional investors have also increased their holdings, with analysts giving ResMed a "Moderate Buy" rating and an average target price of $297.00. The company recently exceeded quarterly EPS and revenue estimates, and declared a quarterly dividend of $0.60 per share.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-18 | Mizuho | $520 | $505 | +3% |
| 2025-12-15 | Morgan Stanley | $425 | $425 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-18 | Mizuho | main | Outperform |
| 2025-12-15 | Morgan Stanley | down | Underweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 2 ($3.12M) |
| Sells | 4 ($14.79M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 29.8% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 2 / 7 |

**Top Holders:**
- Vanguard Group Inc: 6.5% (-3.8%)
- Blackrock Inc.: 5.5% (-3.7%)
- Sanders Capital, LLC: 4.7% (-3.9%)
- State Street Corpora: 3.3% (-5.9%)
- JPMORGAN CHASE & CO: 2.6% (+82.2%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-2.3% 5d) with bearish MACD, trend may be turning.
2. Heavy insider selling: $15M sold (4 transactions in 90 days).
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.29 suggests fair value with growth premium. Forward P/E 15.6x stretched relative to 8% growth. Quality metrics strong (ROE 136%, ROA 12%). Balance sheet: $3.1B free cash flow. Insider selling cluster ($14.8M in 90 days), potential headwind. Institutional flow bullish (2 buying vs 7 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $109.2B |
| Beta | 1.37 |
| 52W Range | $289.98 - $520.00 |
| Short Interest | 3.1% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.29 |
| Forward P/E | 15.6 |
| Current P/E | 16.8 |
| YoY Growth | 7.6% |
| EPS Direction | RISING |

### Technicals

MRS_20 deteriorating from -1.4% to -3.7% (-2.3% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 7.7pp (needs >4.0% for momentum thesis). AM_20 at -4.4% indicates price below own 20MA trend. Underperforming sector by 4.1pp, stock-specific weakness. Long-term uptrend intact (above SMA200 at 1.18x) but short-term weakness (below SMA20). MACD histogram bearish (-4.41), momentum weakening. RSI neutral at 43. OFD pattern: -MUN (Resistance).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -3.70% (CS: 14) | Weak |
| RSI_14 | 42.7 | Neutral |
| MACD Histogram | -4.41 | Bearish |
| vs SMA20 | 0.955x | Below |
| vs SMA50 | 0.999x | Below |
| vs SMA200 | 1.180x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $466.42
- **Stop Loss:** $441.72 (5.3% risk)
- **Target:** $515.82 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 38
- **Position Value:** $17,723.96
- **Portfolio %:** 17.72%
- **Risk Dollars:** $950.00
- **Risk Per Trade:** 0.95%
- **Modifiers:** L1 95% | L2 100% | Combined 0.95x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 0.95x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with cautious positioning ahead of CPI data. VIX at moderate 16.87 with positive yield curve suggesting stable growth, but narrow breadth at 51.8% indicates selective participation. Banking sector optimism and corporate resilience provide support, though AI volatility creates pockets of uncertainty.*

### Earnings

**Next:** 2026-01-23 (Est: $7.46)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $5.73 | $6.96 | +21.6% |
| 2025Q2 | $6.32 | $6.84 | +8.2% |
| 2025Q1 | $5.75 | $6.45 | +12.1% |
| 2024Q4 | $6.14 | $6.22 | +1.2% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*